EU regulatory reforms aim to unlock medtech innovation

  • Home
  • Newsroom
  • EU regulatory reforms aim to unlock medtech innovation
EU regulatory reforms aim to unlock medtech innovation - Axcellant

EU regulatory reforms aim to unlock medtech innovation

  1. maj 30, 2025

The EU is moving forward with key upgrades to its medical device and diagnostics regulations, specifically under the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).

Following years of regulatory bottlenecks, these changes are especially relevant to developers of diagnostics and Software as a Medical Device (SaMD).

At Axcellant, we help companies navigate this evolving landscape through trial design, submissions, and implementation. Greater predictability and clarity in the system open the door to faster innovation — a goal we fully support.

See how we guide medtech and diagnostics teams across the EU regulatory landscape.

Read more

Insights from Turku PET Symposium 2025

Axcellant participated in the PET Symposium 2025, held in Turku, marking 50 years of PET radiochemistry at the Turku PET…

Gene therapy expands beyond oncology — and brings new challenges

Gene therapies now account for most ATMP clinical trials, with a balanced distribution between in vivo and ex vivo approaches.…

How US NIH funding cuts may impact global health innovation

Academic medical centers in the US are voicing concern over reduced funding from the National Institutes of Health (NIH). While…